Skip to main content
. Author manuscript; available in PMC: 2015 Dec 8.
Published in final edited form as: J Neurochem. 2014 Apr 2;130(1):115–125. doi: 10.1111/jnc.12706

Fig. 3.

Fig. 3

(A) LA treatment increases phosphorylation of GSK3βser9, and E2 treatment decreases GSK inhibition in comparison to OVX controls. Bars with SE show the ratio of (pGSK3βser9/actin): (totalGSK3β/actin) expressed in 3xTg Alzheimer’s disease (AD) mouse hippocampus. (B) LA treatment increases expression of beta-catenin. Bars with SE show ratio of beta-catenin/actin expressed in 3xTg hippocampus. (C) Representative western blots of 3xTg AD hippocampus. (D) OVX-associated decrease in cortical brain-derived neurotrophic factor (BDNF) transcription is rescued by LA treatment. Bars with SE show the relative transcription of BDNF to 18S in the cortex of 3xTg mice. Significant difference (p ≤ 0.05) from SHAM (a), from OVX+SAL (b), from OVX+LA (c), from OVX+E2 (d).